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The amino acid transporter asc-1 is not involved in cystinuria.
Background. The human amino acid transporter asc-1
(SLC7A10) exhibits substrate selectivity for small neutral
amino acids, including cysteine, is expressed in kidney, is lo-
cated close to the cystinuria B gene and presents sequence vari-
ants (e.g., E112D) in some cystinuria patients. We have cloned
human asc-1, assessed its transport characteristics, localized its
expression in kidney, searched for mutations in cystinuria pa-
tients, and tested the transport function of variant E112D.
Methods. We used an EST-based homology cloning strategy.
Transport characteristics of asc-1 were assessed by coexpression
with 4F2hc in Xenopus oocytes and HeLa cells. Localization of
asc-1 mRNA in kidney was assessed by in situ hybridization.
Exons and intron-exon boundaries were polymerase chain re-
action (PCR)-amplified from blood cell DNA and mutational
screening was performed by single-stranded conformational
polymorphism (SSCP).
Results. Asc-1 reaches the plasma membrane in HeLa cells,
unlike in oocytes, most probably by interaction with endoge-
nous 4F2hc and presents similar transport characteristics to
those in oocytes coexpressing asc-1/4F2hc. Asc-1 mediates a
substantial efflux of alanine in a facilitated diffusion mode of
transport. Expression of asc-1 mRNA localized to Henle’s loop,
distal tubules, and collecting ducts. Finally, SLC7A10 polymor-
phisms were identified in cystinuria probands and the SLC7A10
sequence variant E112D showed full transport activity.
Conclusion. The lack of expression of asc-1 in the proximal
tubule indicates that it plays no role in the bulk of renal reab-
sorption of amino acids. No mutations causing cystinuria have
been found in SLC7A10. The facilitated diffusion mode of trans-
port and the expression in distal nephron suggest a role for asc-1
in osmotic adaptation.
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Heteromeric amino acid transporters (HATs) are com-
posed of a heavy subunit (rBAT or 4F2hc) and the cor-
responding light subunit, linked by a disulfide bridge
[1, 2]. At present only one light subunit (b0,+AT) of rBAT
has been identified [3], whereas six subunits of 4F2hc
with different amino acid transport activities have been
reported [4]. In addition, two homologous proteins of
these light subunits (asc-2 and AGT-1) form complexes
with as yet unidentified heavy subunits [5, 6]. The amino
acid transport function associated to asc-2 and AGT-1
has been studied in oocytes expressing a fusion pro-
tein of these light subunits with rBAT and 4F2hc [5, 6].
HATs serve for amino acid transport systems with an
obligatory exchange mode of transport, with a few ex-
ceptions. Thus, the following heterodimeric complexes
mediate exchange of amino acids: b0,+AT/rBAT (system
b0,+) [7], LAT-1/4F2hc and LAT-2/4F2hc (system L iso-
forms) [8–10], y+LAT-1/4F2hc and y+LAT-2/4F2hc (sys-
tem y+L isoforms) [11–13], and xCT/4F2hc (system xc−)
[14, 15]. In contrast, oocytes expressing asc-1/4F2hc or
asc-2 fusion proteins with rBAT or 4F2hc show induction
of amino acid efflux to amino acid–free medium, suggest-
ing a facilitated diffusion in addition to exchange mode
of transport [6, 16]. The transport characteristics of asc-1
resembles system asc described in trout lymphocytes and
hepatocytes, whereas asc-2 appears to be the system asc
found in trout red blood cells [17].
Three HATs (b0,+AT/rBAT, y+LAT-1/4F2hc, and
LAT-2/4F2hc) are involved in renal reabsorption of
amino acids. System b0,+ (i.e., the b0,+AT/rBAT het-
erodimeric complex) is the main apical reabsorption sys-
tem for cystine and also mediates renal reabsorption of
dibasic amino acids. This is evidenced by coimmunopre-
cipitation studies of rBAT and b0,+AT in kidney brush-
border membranes [3] and by the fact that mutations in
rBAT (encoded by SLC3A1) or in b0,+AT (encoded by
SLC7A9) cause cystinuria [18, 19]. Moreover, the knock-
out of Slc3a1 and Slc7a9 in mice also results in cystinuria
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[20, 21]. Cystinuria is an inherited amino aciduria char-
acterized by hyperexcretion of cystine and dibasic amino
acids in urine [22]. The basolateral system y+L in kid-
ney proximal tubule (i.e., y+LAT-1/4F2hc) mediates the
efflux of dibasic amino acids, as evidenced by the fact
that mutations in y+LAT-1 (encoded by SLC7A7) cause
lysinuric protein intolerance, an inherited dibasic amino
aciduria [23, 24]. Finally, LAT-2/4F2hc (a system L iso-
form) has been suggested to have major role in the
transepithelial flux of L-cystine in the proximal tubule be-
cause it mediates the basolateral efflux of cysteine (i.e.,
the reduced form of cystine), as evidenced in the renal
proximal tubule cell line OK [25].
Asc-1 exhibits substrate selectivity for L- and D- small
neutral amino acids, including D-serine, glycine, and
L-cysteine [16]. Human asc-1 is expressed mainly in pla-
centa, brain, kidney, and heart [26]. In brain, asc-1 is
restricted to neuronal structures, with the highest expres-
sion in presynaptic complexes, suggesting a role in the
synaptic clearance of D-serine [27]. Because D-serine is an
agonist at the strychnine-insensitive glycine binding site
on the NMDA receptors and these receptors have been
related to some important physiologic and patophysio-
logic processes (e.g., learning, schizophrenia, depression,
epilepsy), alteration of the clearance of D-serine via asc-1
might have profound physiological consequences [28]. In
kidney, it has been suggested that SLC7A10 could be an
additional gene for cystinuria, and therefore with a role
in renal reabsorption of cistine/cysteine [29]. SLC7A10 is
located in the vicinity of SLC7A9, the cystinuria B gene,
within the 19q13.1 region [26], and SLC7A10 sequence
variants (e.g., E112D) that associate with a few cystin-
uria patients have been reported [29]. To understand the
physiological role of asc-1 in kidney and to test its possible
involvement in cystinuria we assessed its transport char-
acteristics, localized its expression in kidney, searched
for mutations in SLC7A10 in cystinuria patients, and fi-
nally tested the transport function of the sequence variant
E112D.
METHODS
cDNA isolation
Using the amino acid sequence of y+LAT-1 protein as a
query in a tBLASTn search versus dbEST [30], we identi-
fied a highly similar human EST (AI123040, correspond-
ing to IMAGE clone 1509931) mapping to chromosome
19q13.1 in the previously defined cystinuria type B locus
[19, 31]. The insert of the IMAGE clone was then used
as a probe to screen a human kidney cDNA library. A
full length cDNA clone of 1807 bp was obtained, encod-
ing the previously reported human asc-1 protein [26], and
was cloned in pBluescript SK−.
Oocytes, injections, and uptake measurements
Oocyte origin, management, injections, and uptake
measurements were as described elsewhere [32]. Defol-
liculated stage VI oocytes were injected with 10 ng/oocyte
of human 4F2hc or asc-1 alone or in combination. Synthe-
sis of human 4F2hc cRNA was as described [32]. Human
asc-1 cRNA was obtained by cutting asc-1 in pBluescript
SK− with XhoI and using T3 polymerase.
Plasmid construction and site-directed mutagenesis
To create a N-myc-tagged asc-1, asc-1 cDNA was poly-
merase chain reaction (PCR)-amplified with primers 5′-
TATATAGTCGACATGGCCGGCCACACGCAG-3′
(containing a SalI site) and 5′-ATATTGCGGCCGCAA
AACGACGGCCAGTGAATTG-3′ (containing a NotI
site). The PCR product was digested with SalI and NotI
and cloned into pNKS2-myc. For construction of the
asc-1(E112D) mutant, the QuickChange Site-Directed
Mutagenesis Kit was used (Stratagene, La Jolla, CA,
USA), following the manufacturer’s protocol. The muta-
genic primer was (sense strand, the mutated nucleotide
is indicated by parenthesis) 5′-CGCCTACGTCACAGA
(C)ATCTTCGGGGGCC-3′. The success of mutagenesis
was checked by the loss of a BglII site. Proper construc-
tion of plasmids and mutated cDNA were confirmed by
complete sequencing. All sequences carried out in this
work were performed as described [9]. For expression
in HeLa cells, 4F2hc-pCMV2, rBAT-pCDNA3 [33],
asc-1-pCDNA3 (wild-type and the E112D mutant),
cloned between the restriction sites EcoRI and XhoI)
and N-myc tagged asc-1-pCDNA3 (cloned between the
restriction sites HindIII and NotI) were used.
Patients
We studied 22 cystinuria patients (21 Spanish and one
Italian) from independent families, in which no mutations
or only one mutation had been found after an exhaus-
tive analysis of SLC3A1 or SLC7A9. Urinary excretion
of cystine and dibasic amino acids in the obligate het-
erozygotes was used to classify most of the probands in
cystinuria subtypes. Most of these independent probands
excrete cystine and dibasic amino acids in the urine in
the range of cystinuria homozygotes or compound het-
erozygotes and above the control range. In addition, two
Spanish independent probands had a urinary amino acid
profile similar to their parents transmitting the disease
and within the upper range of SLC7A9 heterozygotes
that produced cystine calculi.
Analysis of SLC7A10 gene
DNA was extracted from peripheral blood samples ob-
tained after informed consent following standard pro-
cedures. The SLC7A10 gene has 11 exons. The eleven
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Table 1. Conditions used for SLC7A10 exons amplification
Temp
Exon Name Primer sequences (5′ to 3′) (◦C) Enhancera
1 P5IF1 GGACAGACGGGGCA 66 2×
GCGCA
P5IR1b CCTCGTTCGGAGCG 66
GCTGC
2 P5IF2 ACAGAAGGCCGGGCT 64 0.5×
GCGAA
P5IR2 CCATTCCCAAGAGGG 64
TGTCC
3 P5IF3 TCTGGGCAGCTTGAG 64 2×
CCACT
P5IR3b GGGCAGGTGGCTGAT 64
CTGTA
4 P5IF4b CATGGTCCACTGTGA 60 1×
AAGGT
P5IR4b TCAGCTCCTCGAAGT 62
GTCCT
5 P5IF5 GTAGGGCCGAGTCGG 66 2×
GGTAA
P5IR5b AGAGGGCCTGGCT 64
GCTTC
6 P5IF6 TGCACCCTCAGGAGC 66 0.5×
TGACG
P5IR6 CACAGTAGAGAGGCCAT 66
GTGTA
7 P5IF7b CCTTACACATGGCCTC 64 No
TCTAC
P5IR7b CCCACGGCATGACT 64
GGTGC
8 P5IF8b GCTGAGACCCAGGA 62 1×
TGTGG
P5IR8b AGGTCCTGCATTGCC 64
GGGTA
9 P5IF9 GGCCAGGGCTCATC 64 1×
CTGCA
P5IR9 GCAGGGGTGGCTCT 66
GGCAG
10 P5IF10b CCCTGCACCATCGGT 64 No
GTTTC
P5IR10 AGGGAGGTCTGGTCT 66
CCAGG
11 P5IF11b GCTGCCTCGTTGAG 62 1×
GGACT
P5IR11 CAGAAACAACTGCTTCA 60
GTCTC
aFinal relative concentration of “polymerase chain reaction (PCR) Enhancer
Solution” from 10× stock solution.
bDifferent sequence from Leclerc et al (2001).
pairs of primers used for their amplification are detailed
in Table 1. PCR conditions are the following: 94◦C 30
seconds, 58◦C 30 seconds, 68◦C 45 seconds; 35 cycles.
Each amplification reaction was performed using 100 ng
of patient DNA, deoxynucleoside triphosphates (dNTPs)
(200 lm of each), PCR Enhancer System (Invitrogen,
Carisbad, CA, USA) for all exons but seven and ten
that needed PCR buffer containing MgCl2 (1.5 mmol/L
as a final concentration) (Table 1), Taq polymerase
(0.02 units/mL) (Perkin Elmer, Wellesley, MA, USA),
and primers (0.35 mmol/L of each), in a final volume
of 50 lL. The mutational screening of the probands
was performed by DNA-single-stranded conformational
polymorphism (SSCP). We ran premade 12.5% acry-
lamide SSCP gels (ExcelGel DNA Analysis Kit) (Phar-
macia Biotech, Uppsala, Sweden) at 5◦C. A 20-minute
prerun at 100 V, 23 mA, and 5 W was performed, fol-
lowed by a 3-hour 20-minute run at 600 V, 30 mA, and
18 W. Silver staining of these gels was completed with
the DNA Silver Staining Kit on an automatic gel stainer
(Pharmacia Biotech). Our group had previously used this
technique for the analysis of SLC3A1 and SLC7A9
(International Cystinuria Consortium, 1999); bands
showing an altered mobility in electrophoresis were then
sequenced. In all cases, sequence on both strands of
the PCR products was performed with the same set of
primers used for the amplification by automated systems.
Sequences were then analyzed using the program Se-
quencher version 3.0 (Gene Codes Corporation, Ann Ar-
bor, MI, USA). All sequence variants were checked in
controls by restriction and/or SSCP analysis.
Statistical analysis
Hardy-Weinberg equilibrium of the different geno-
types was evaluated for each polymorphism by
chi-squared (Table 2). Control genotypes follow Hardy-
Weinberg equilibrium (data not shown), so we can
assume no stratification for our population. Statistical sig-
nificance of differences between distributions for geno-
types was evaluated using Fisher exact test with a 2 ×
2 contingency table, comparing the patient group versus
control group. Significance was considered when P <0.05.
HeLa cell transfections
HeLa cells were grown in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS), 100 U/mL penicillin, and 0.1 mg/mL
streptomycin (D10) at 37◦C in a humidified atmosphere
containing 5% CO2. The DMEM medium contained
340 lmol/L Arg, 666 lmol/L Lys, 200 lmol/L cystine,
4.0 mmol/L Gln, 399 lmol/L Gly, 800 lmol/L Ile,
800 lmol/L Leu, 201 lmol/L Met, 400 lmol/L Phe,
400 lmol/L Ser, 798 lmol/L Thr, 78 lmol/L Trp,
397 lmol/L Tyr, and 803 lmol/L Val. Transfections
were performed by standard calcium phosphate pre-
cipitation in 10 cm diameter plates with a mixture of
DNA containing 2 lg of green fluorescence protein
(pEGFP) (Clonetech, Palo Alto, CA, USA), 9 lg of asc-1-
pCDNA3, and 9 lg of 4F2hc-pCMV2 or rBAT-pCDNA3.
When 4F2hc, rBAT or asc-1 (wild-type or E112D mutant)
were transfected alone the DNA transfection mixture
contained 2 lg of pEGFP and 18 lg of 4F2hc-pCMV2,
rBAT-pCDNA3, or asc-1-pCDNA3. After overnight in-
cubation with the DNA-calcium phosphate coprecipitate,
cells were extensively washed with phosphate-buffered
saline (PBS) and trypsinized. Then 150,000 cells in 1 mL
of D10 were plated per well on a 24-well plate for up-
take and efflux measurements, 300,000 cells on a 12-well
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Table 2. Sequence variants found in SLC7A10 gene in cystinuric patients
Allelic frequencies (%)
Patients Controls
Sequence variants This study Leclerc et al (2001) This study v 2 Leclerc et al (2001)
IVS4 + 48C→G 2.3 (1/44) — 8.2 (9/110) 1.63 —
IVS4-21C→G 2.3 (1/44) — 8.2 (9/110) 1.63 —
IVS6-11T→C 55 (22/40) 30 (6/20) 56.5 (52/92) 0.01 >1
IVS8-17G→A 2.3 (1/44) — 3.1 (2/64) 0.07 —
c.1473G→T (T458T) 4.8 (2/42) 5.0 (1/20) 7.3 (7/96) 0.28 >1
c.435G→C (E112D) — 5.0 (1/20) — 0 (0/238)
c.267G→A (S56S) — 5.0 (1/20) — 0 (0/238)
IVS7 + 20G→T — 5.0 (1/20) — 0 (0/204)
The sequence variants found in this study and the described by Leclerc et al [29] are shown. The ratios between parentheses indicate the number of positive alleles
versus the total number of alleles analysed. v 2 compares the frequency of the sequence variants identified in the present study in patient and control populations. None
of the frequencies reaches the level of significance (v 2 > 3.84 for P ≤ 0.05; 1 degree of freedom).
plate for amino acid content measurement, or 600,000
cells on a 6-well plate for Western-blotting analysis. Cells
were then kept at 33◦C or 37◦C for 48 hours before ex-
periments. Transfection efficiency was checked by ana-
lyzing an aliquot of cells of each individual transfection
group for GFP expression by fluorescence-activated cell
sorting using an EPICS XL Coulter cell sorter (Serveis
Cientifico-Te`cnics, Parc Cientı´fic de Barcelona, Spain).
The percentage of positive cells was defined as the frac-
tion beyond the region of 99.9% of non-GFP transfected
cells. Transfection efficiency of GFP ranged from 40%
to 80% in different experiments. Transfections with an
efficiency <40% were discarded.
Localization of asc-1 and 4F2hc expression by
confocal microscopy
For immunofluorescence labeling, transfected HeLa
cells grown on glass coverslips were rinsed briefly in PBS,
fixed in 3% paraformaldehyde-PBS for 10 minutes, in-
cubated in 50 mmol/L NH4Cl-PBS for 10 minutes, and
then in 20 mmol/L glycine-PBS for 10 minutes. To im-
munolocalize myc-asc-1 or 4F2hc, cells were incubated
in 0.1% Triton X-100 in PBS for 10 minutes. Other-
wise, to immunolocalize surface 4F2hc, cells were not
permeabilized. Then, cells were washed three times in
PBS, blocked in 10% fetal bovine serum (FBS)-PBS for
30 minutes, and exposed to primary antibody 9E10 anti-
myc (ATCC, Manassas, VA, USA) diluted 1/500 in 10%
FBS-PBS or antibody CD98 anti-4F2hc (Immunotech,
Marseille, France) diluted 1/50 in 10% FBS-PBS. Cov-
erslips were washed three times, and incubated with
7.5 mg/mL Texas red-conjugated goat antimouse (Molec-
ular Probes, Leiden, The Netherlands) for 1 hour. Fi-
nally, coverslips were washed three times in PBS and
mounted with immunofluorescence medium (Valeant,
Costa Mesa, CA, USA). Confocal microscopy was per-
formed at the Serveis Cientı´fico-Te`cnics of the Parc
Cientı´fic de Barcelona.
Uptake and efflux measurements in
HeLa-transfected cells
A total of 24-well plates, with 1 mL of D10 medium
per well, were placed in a dry incubator at 37◦C 1 hour
prior to the transport experiment. For uptake measure-
ments, cells were washed twice with 1 mL of the transport
medium [137 mmol/L N-methyl-D-gluconate (NMDG)
or 137 mmol/L NaCl, 2.8 mmol/L CaCl2, 1.2 mmol/L
MgSO4, 5.4 mmol/L KCl, and 10 mmol/L HEPES, pH 7.5,
equilibrated at 37◦C]. Subsequently, 200 lL of the trans-
port medium with substrate [50 lmol/L L-[3H]alanine
or L-[3H]serine (2.5 lCi/mL)] was added and cells were
incubated for different periods. To determine linear trans-
port rates, cells were incubated for 1 minute (linear con-
ditions; data not shown). After incubation, the uptake
medium was removed and cells were washed three times
in 1 mL of cold (4◦C) transport medium. Nonspecific
binding was assessed by quick addition and immediate
removal of the transport medium at 4◦C. After wash-
ing, cells were lysed by addition of 250 lL 0.1 mol/L
NaOH, 0.1% sodium dodecyl sulfate (SDS) per well, 100
lL were used to count radioactivity and 20 lL were used
to measure the protein content in the well using the BCA
Protein Assay Kit (Pierce, Rockford, IL, USA). Ra-
dioactivity was measured in a beta scintillation counter
(Beckman LS 6000TA; Beckman Instruments, Fullerton,
CA, USA).
For efflux measurements, transfected HeLa cells were
preloaded by incubation in transport medium contain-
ing 50 lmol/L L-[3H]alanine (5 lCi/mL) for 5 minutes.
The cells were then washed three times with ice-cold
transport medium and incubated in the efflux solution in
the presence or absence of 1 mmol/L L-alanine, L-serine,
L-leucine, or L-proline. The radioactivity in the medium
and the remaining radioactivity in the cells were mea-
sured. Efflux rates were measured at 15 seconds and ex-
pressed as released nmol alanine/mg protein and were
calculated as follows: [radioactivity released into the
medium/total radioactivity in the system] × [intracellular
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content of alanine expressed in nmol/mg protein] where
[total radioactivity in the system] = [radioactivity remain-
ing in cells] + [radioactivity released to the medium].
Amino acid content of transfected HeLa cells
Cells in 12-well plates were washed three times with
2 mL of ice-cold PBS. For deproteinization, 200 lL of
10% sulfosalicylic acid were added per well. The mixture
was centrifuged at 12,000g for 5 minutes. The supernatant
was removed and stored at −20◦C before assay of intra-
cellular amino acids. The pellet was dissolved in 1 mL of
0.1 N NaOH for protein determination by using the BCA
Protein Assay Kit (Pierce). Total intracellular amino acid
content was determined by cation exchange chromatog-
raphy on an automatic Amino Acid Analyzer (Beckman
model 6300). The cell amino acid content is expressed as
nmol amino acid/mg protein.
Northern blot analysis
A human adult poly(A+) membrane from Clontech
was used. A band of 389 pb (corresponding to human
asc-1 cDNA region nt 1241-1630) was amplified from
human asc-1 cDNA using primers 5′-CTGCACTCCAC
AGGCCCATCAA-3′ and 5′-CACCTCCTCAATAAA
CAAC-3′. The band was purified, labeled with [a-32P]
deoxycytidimine triphosphate (dCTP) (Amersham Phar-
macia Biotech) using random oligonucleotide-priming la-
beling kit (Amersham Pharmacia Biotech), and used as
a probe. Hybridization and washing conditions were as
recommended by Clontech.
In situ hybridization
Sense and antisense cRNA probes were labeled with
digoxigenin-11-UTP (Roche Molecular Biochemicals,
Basel, Switzerland) by transcription of an asc-1 fragment
(26-239 nt of the cDNA) cloned in pGEM-T Easy vec-
tor (Promega, Madison, WI, USA), using the mMessage
mMachine transcription kit (Ambion, Austin, TX, USA).
Preparation of kidney sections and in situ hybridization
were performed as described [9].
RESULTS
Asc-1 required 4F2hc for its functional expression in
Xenopus oocytes
As shown in Figure 1, asc-1 by itself did not induce
L-[3H]alanine transport. Expression of 4F2hc alone re-
sulted in a significant induction of L-alanine transport,
whereas the co-expression of 4F2hc and asc-1 resulted
in greater L-alanine uptake. This indicates that 4F2hc
is indispensable for the functional expression of asc-1.
The asc-1/4F2hc coexpressed transport of L-alanine was
sodium-independent (Fig. 1) and was completely abol-
ished by a 100-fold excess of L-neutral amino acids of
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Fig. 1. Coexpressed alanine transport activity by asc-1/4F2hc in Xeno-
pus oocytes. Oocytes were injected with asc-1 cRNA, 4F2hc cRNA or
their combination. Three days after injection, the uptake of 50 lmol/L L-
[3H]alanine in the absence () or presence () of 100 mmol/L NaCl was
determined for 5 minutes. Amino acid uptakes rates (pmol/5minutes per
oocytes) were calculated by subtracting the uptake of the noninjected
group from that of the cRNA-injected groups. The amino acid uptake
activity of uninjected oocytes was 2.4 ± 0.3 and 2.9 ± 0.4 pmol/5minutes
per oocytes in the absence and in the presence of sodium, respectively.
Data (mean ± SEM) correspond to a representative experiment with
seven to eight oocytes per group (N = 9 independent experiments).
small side chain (e.g., alanine, serine, threonine, and cys-
teine) (data not shown). Other L-neutral amino acids
(e.g., leucine, histidine, valine, and asparagine) inhibited
transport to a lower extend, and L-dicarboxylic (e.g., glu-
tamate) and dibasic (e.g., lysine and ornithine) amino
acids did not inhibit transport at all (data not shown).
These results are in full agreement with previous studies
with mouse and human asc-1 in oocytes [16, 26].
As stated above, expression of 4F2hc alone resulted in
a variable but significant induction of alanine transport in
oocytes (4.3 ± 1.2 pmol/5 minutes per oocyte in nine inde-
pendent experiments). This 4F2hc-induced transport of
alanine showed characteristics of system asc: (1) sodium
independence (Fig. 1) and (2) a similar amino acid pattern
of inhibition than that of asc-1/4F2hc-induced transport
(data not shown). This suggests that 4F2hc induced sys-
tem asc by interaction with an endogenous asc subunit.
This is in agreement with the report of system asc trans-
port activity in Xenopus oocytes [34]. This 4F2hc-induced
transport compromises the level of induction of system
asc transport activity by coexpression of asc-1 with 4F2hc
over background conditions (2.8 ± 0.3-fold over 4F2hc-
expressing oocytes) (N = 9).
Functional expression of asc-1 in HeLa cells
In order to express the asc-1 amino acid transport activ-
ity in an expression system with lower background than
oocytes, HeLa cells were transiently transfected with asc-
1 and 4F2hc alone or together. As shown in Figure 2A,
transfection of 4F2hc did not result in the induction of L-
alanine transport over background (e.g., nontransfected
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Fig. 2. In HeLa cells, asc-1 induces alanine transport due to the in-
teraction with endogenous 4F2hc. (A) Transfection of human asc-1 in
HeLa cells resulted in increased L-[3H]alanine transport. Cells were
transfected with 4F2hc or asc-1 alone or in combination, and grown
for 48 hours. Cells transfected with 4F2hc alone showed identical lev-
els of transport as untransfected HeLa cells. In contrast, transfection
with human asc-1 or asc-1/4F2hc increased the L-3H-alanine transport
(35- and 41-fold over background, respectively). (B) Localization of
4F2hc and myc-asc-1 in transfected HeLa cells. HeLa cells were trans-
fected with N-myc-tagged asc-1 alone or in combination with 4F2hc and
processed for immunocytochemistry. Two days after transfection, cells
were fixed, permeabilized, and incubated with antibody 9E10 anti-myc
or CD98 anti-4F2hc, or not permeabilized and incubated with antibody
CD98 anti-4F2hc. The N-myc epitope did not significantly affect amino
acid transport activity (70% to 85% of the asc-1–induced transport in
two separate experiments; data not shown). The induced uptake of 50
lmol/L L-alanine in nmol/1 minute per mg protein was 0.07 ± 0.08
for 4F2hc, 2.0 ± 0.3 for myc-asc-1, and 2.3 ± 0.2 for myc-asc-1/4F2hc–
transfected cells.
cells). In contrast, asc-1- or asc-1/4F2hc–transfected cells
showed induction of L-alanine transport in a similar level
(∼40-fold higher than transport in cells transfected with
4F2hc alone). This suggests that endogenous 4F2hc is
used for the functional expression of asc-1. We have
obtained similar results with other 4F2hc light subunits
like LAT-2 and xCT transfected in HeLa cells (data not
shown).
The expression of myc-asc-1 and 4F2hc in HeLa cells
was next studied. Nontransfected HeLa cells showed ex-
pression of 4F2hc at the cell surface in nonpermeabi-
lized cells (Fig. 2B). Moreover, permeabilized HeLa cells
showed also intracellular expression of 4F2hc (Fig. 2B).
Detection of myc-asc-1 with anti-myc antibodies requires
permeabilization of the cells, because the myc tag was
fused to the N-terminus of asc-1, with a predicted location
inside the cell. Myc-asc-1 showed expression at the cell
membrane both in HeLa cells transfected with myc-asc-1
alone or cotransfected with myc-asc-1/4F2hc (Fig. 2B).
Transfection of myc-asc-1 alone or cotransfected with
4F2hc resulted in a higher expression of 4F2hc at the
cell membrane (Fig. 2B). These results strongly suggest
that asc-1 uses endogenous 4F2hc to express its transport
activity in HeLa cells.
The functional properties of asc-1 were examined
in HeLa cells transfected with asc-1 alone. The asc-
1–mediated amino acid transport was sodium inde-
pendent. Thus, the induced uptake of 50 lmol/L
L-[3H]alanine (calculated by subtracting the uptake in
4F2hc-transfected cells) in the absence and in the pres-
ence of sodium was 1.2 ± 0.1 and 1.4 ± 0.2 nmol/mg
of protein, respectively). Similar to alanine, asc-1 in-
duced sodium independent L-serine uptake in trans-
fected HeLa cells (data not shown). The uptake of
L-[3H]alanine was saturable and followed Michaelis-
Menten kinetics with a Km value of 35.4 ± 5.0 lmol/L
(Fig. 3A). The inhibition pattern of asc-1–induced L-
alanine uptake is shown in Figure 3B. A 100-fold excess
of L- and D-neutral amino acids with small side chain, in-
cluding the analogue AIB, almost abolished completely
the asc-1–induced transport. Dicarboxylic and dibasic
amino acids, proline, tyrosine, and the N-methyl derivate
of AIB (MeAIB) did not inhibit at all. Other neutral
amino acids produced a variable degree of inhibition. This
inhibition pattern is identical to that described previously
for mouse and human asc-1 in oocytes [16, 26].
To study the exchange mode of transport of asc-1,
the efflux of L-[3H]alanine was studied. Efflux measure-
ments in cells require preloading of cells with the labeled
substrate and the consequent appearance rate of the
radiotracer in the medium. HeLa cells transfected with
asc-1 or 4F2hc were incubated for 5 minutes with 50
lmol/L L-alanine, and the intracellular content of amino
acids were assessed. As shown in Figure 4A, no signifi-
cant differences in the intracellular content of the most
abundant preferred amino acid substrates of asc-1 were
observed between asc-1–transfected and 4F2hc-
transfected (control) cells. Similarly, transfection of
asc-1 did not alter the intracellular concentration of
other amino acids (data not shown). The intracellular
content of L-alanine determined was used to calculate
the efflux rate of L-alanine in the following experiments
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Fig. 3. Characteristics of alanine transport induced by asc-1 in trans-
fected HeLa cells. HeLa cells were transfected with 4F2hc or asc-1 and
incubated for 2 days. (A) Kinetic analysis of L-alanine transport in-
duced by asc-1. The uptake of L-[3H]alanine in the absence of sodium
was determined for 1 minute at different substrate concentrations (1,
5, 10, 25, 75, 150, 400, and 1200 lmol/L). The transport activity level in
4F2hc-transfected cells was subtracted from that of asc-1–transfected
cells. Data (mean ± SEM) correspond to a representative experiment
with four replicas per group. Kinetic parameters were: Vmax = 8.0 ±
0.3 nmol 1 min mg protein; Km = 35.4 ± 5.0 lmol/L (GraphPad Prism
program). (B) Inhibition pattern of L-[3H]alanine transport in asc-1–
transfected HeLa cells. The uptake of L-[3H]alanine in the absence of
sodium for 1 minute was measured in the absence (control) or in the
presence of 5 mmol/L of the indicated amino acids or analogues. The
induced transport was 0.06 ± 0.02 and 3.2 ± 0.3 nmol alanine/1 minute
per mg protein in 4F2- and asc-1–transfected cells, respectively. Data
(mean ± SEM) represent percentages of the amino acid residual trans-
port in the presence of the inhibitor. Data correspond to two to three
independent experiments, with four replicas per group.
where HeLa cells were preloaded with 50 lmol/L L-
[3H]alanine for 5 minutes (Fig. 4B). Efflux of L-alanine in
4F2hc-transfected cells was not affected by the presence
of amino acids in the medium. In contrast, in asc-1–
transfected cells, L-alanine and L-serine (i.e., substrates
of asc-1), but not L-leucine and proline, transstimulated
efflux of L-alanine. Thus, efflux to medium containing
L-alanine or L-serine was ∼70% greater than to amino
acid-free medium. Interestingly, efflux of L-alanine from
asc-1-transfected cells in amino acid–free medium (or
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Fig. 4. Exchange of intracellular alanine by asc-1 in transfected HeLa
cells. HeLa cells were transfected with 4F2hc or asc-1 and incubated
for 2 days. (A) Intracellular content of the most abundant small neu-
tral amino acids after 5 minutes’ incubation with 50 lmol/L L-alanine.
The amino acid content expressed as nmol/mg protein was measured in
triplicates from four independent transfection experiments. After incu-
bation with alanine, 4F2hc- and asc-1–transfected cells showed similar
intracellular content of small neutral amino acids, which are substrates
of system asc. No significant differences were found in the intracellu-
lar content of the other amino acids (data not shown). (B) To monitor
exchange of intracellular alanine, cells were loaded by incubation with
50 lmol/L L-[3H]alanine for 5 minutes. Then, the efflux rate of ala-
nine to extracellular medium containing no amino acids or L-alanine
(Ala), L-serine (Ser), L-leucine (Leu), or L-proline (Pro) at 1 mmol/L
was measured. The efflux in 4F2hc-transfected cells was not transstim-
ulated by the presence of amino acids in the extracellular medium. In
contrast, in asc-1–transfected HeLa cells, the efflux was transstimulated
by substrate amino acids (e.g., L-Ala and L-Ser) (∗P ≤ 0.05), but not by
nonsubstrates amino acids (e.g., L-Leu and L-Pro). As shown, efflux of
alanine in asc-1–transfected cells was higher than in 4F2hc-transfected
cells regardless the presence of amino acids (#P ≤ 0.05). This suggests
that asc-1/4F2hc does not act as an obligatory amino acid exchanger.
Data, expressed as nmol alanine/mg protein in 15 seconds, represent the
mean ± SEM from three independent experiments with four replicas
each.
in medium containing L-leucine or proline) was also
greater than in 4F2hc-transfected cells. Thus, 30% to
40% of the L-alanine efflux via asc-1 was independent of
the presence of asc-1 substrates in the medium.
Role of SLC7A10 in cystinuria
SLC7A10 has been proposed as a candidate gene for
cystinuria for several reasons [29]: (1) the chromosomal
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location of SLC7A10 in 19q13.1, in the vicinity of the
cystinuria type B gene (SLC7A9), (2) asc-1 mRNA is
expressed in kidney, (3) cysteine is a substrate for asc-
1, and (4) three cystinuria-specific SLC7A10 sequence
variants have been detected. To check this hypothesis we
studied localization of the SLC7A10 mRNA expression
in kidney and searched for mutations of this gene in our
cohort of cystinuria patients.
Initially, we studied the tissue distribution of expres-
sion of asc-1 in human tissues by Northern blot. Multiple
hybridizing bands at 1.3 kb, 2.0 kb, 4.6 kb, and 6.0 kb were
detected in various tissues including brain, kidney, skele-
tal muscle, heart, liver, and placenta (data not shown). A
similar expression pattern has been described previously
[26]. In kidney, the 2.0 kb transcript was expressed pre-
dominantly (data not shown). Expression of asc-1 mRNA
in human kidney was assessed by in situ hybridization
(Fig. 5). The asc-1 mRNA localized to distal tubules and
collecting ducts in the renal cortex, and more conspicu-
ously in thin limbs of Henle’s loops, distal tubules, and
collecting ducts in the renal medulla. In contrast, no sig-
nal was detected in glomeruli or proximal tubules. This
suggests that SLC7A10 has no role in cystinuria since
the bulk (∼99%) of renal reabsorption of cystine occurs
in the proximal tubule [35]. Beside this, the description
of cystinuria-specific sequence variants in SLC7A10 [29]
fosters us to search for mutations in this gene in 22 pa-
tients with cystinuria with incomplete description of mu-
tations after an exhaustive analysis of the two cystinuria
genes known so far (SLC3A1 and SLC7A9). Mutational
analysis was performed in the exon-intron boundaries
and the coding region of the gene. Table 2 summarizes the
five SLC7A10 sequence variants identified in these pa-
tients. Four of them correspond to intronic sequence vari-
ants, which do not likely affect splicing as predicted by the
compilation of Senapathy, Shapiro, and Harris [36]. The
last identified sequence variant is a silent G→T transver-
sion affecting residue T458. This last variant and IVS6-
11T→C were also identified in the study of Leclerc et al
[29]. In contrast, the other previously described variants,
including 435G→C, the only one that results in an amino
acid residue change (E112D), has not been identified in
our selection of patients. The five identified variants in
the present study were also present in control popula-
tion, with similar frequency that in the patients studied
(Table 2).
In order to test further a role of SLC7A10 in cystin-
uria, the amino acid transport function associated with
the sequence variant E112D was assessed. As shown in
Figure 6A, asc-1 (E112D)- and wild-type asc-1–
transfected cells induced similar uptake of 50 lmol/L
L-[3H]alanine and L-[3H]serine. Moreover, the induced
efflux of L-alanine by asc-1 (E112D)- and wild-type asc-
1-expressing cells were also similar in both transstim-
ulated (medium containing L-alanine or L-serine) and
A B
DC
Fig. 5. In situ hybridization of asc-1 mRNA in human adult kidney.
Paraffin-embedded sections of human kidney cortex (A and C) and
outer medulla (B and D) were incubated with antisense (A and B)
or sense (C and D) asc-1 cRNA probes as described in the Methods
section. Asc-1 mRNA-specific detection is restricted to distal tubules
(D), collecting ducts (CD) and thin limbs of the loop of Henle (T).
No signal is detected in glomerulus (G), or proximal tubule (P).
This localizes the asc-1 mRNA expression in the distal nephron (bar,
100 lm).
nontransstimulated conditions (amino acid–free medium
or medium containing L-leucine) (Fig. 6B). In all, these
results do not support the involvement of SLC7A10 in
cystinuria.
DISCUSSION
In the present study, we have shown that asc-1/4F2hc
expressed in HeLa cells induces transport of amino acids
with characteristics of a high-affinity (lmol/L range) and
nonstereospecific system asc, as described previously in
oocytes [16, 26]. Asc-1/4F2hc transporter shows preferred
selectivity for small neutral amino acids (i.e., glycine, ala-
nine, serine, threonine, and cysteine). Here we show that
asc-1/4F2hc mediates significant nontransstimulated ef-
flux of alanine (up to 40% of the total efflux in the pres-
ence of asc-1 substrates in the medium). Similar behavior
was also suggested for mouse asc-1/4F2hc expressed in
oocytes [16]. It has to be mentioned that in the family of
HATs, the distant member asc-2 (with amino acid iden-
tity of 21% between mouse asc-1 and asc-2) also induces
system asc transport activity, with very high-affinity (low
lmol/L range), stereospecificity and preferred selectiv-
ity for glycine, alanine, serine, and threonine [6]. Similar
to asc-1, asc-2 also mediates significant facilitated diffu-
sion in addition to the exchange transport mechanism.
In the context of a cell expressing concentrative neu-
tral amino acid transporters (e.g., systems A, B0, B0,+)
the facilitated diffusion mode of transport induced by
asc-1 and asc-2 suggests a role in the net efflux of small
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Fig. 6. The E112D mutation in asc-1 does not affect the induced asc
transport activity in transfected HeLa cells. Cells were transfected with
4F2hc, wild-type asc-1 or E112D asc-1 and incubated for 2 days. (A)
Analysis of the alanine and serine induced uptake by asc-1 (E112D) mu-
tant. The transport activity induced by L-[3H]alanine and L-[3H]serine
in the absence of sodium for 1 minute was measured in transfected cells.
No significant differences were observed in the induced uptake in wild-
type asc-1- and asc-1 (E112D)-expressing cells. Data (mean ± SEM) are
from a representative experiment with four replicas per group. A second
independent experiment gave similar results. (B) System asc induced
by asc-1 (E112D) in transfected HeLa cells presents transstimulation.
Cells were loaded by incubation with 50 lmol/L L-[3H]alanine for 5
minutes. Then, the efflux rate of alanine to extracellular medium con-
taining no amino acids or L-alanine (Ala), L-serine (Ser,) or L-leucine
(Leu) at 1 mmol/L was measured. The induced efflux in wild-type asc-1-
and asc-1 (E112D)–transfected cells was calculated by subtracting the
efflux in 4F2hc-transfected cells. To express the efflux rate as nmol ala-
nine/mg protein in 15 seconds, the percentage of radioactivity released
was corrected by the intracellular content of alanine (see the Meth-
ods section). Similar to the efflux in wild-type asc-1–transfected cells,
the efflux in asc-1 (E112D)–transfected cells was transstimulated by L-
alanine and L-serine (P ≤ 0.05), but not by L-leucine. Data represent
the mean ± SEM from two independent experiments with four replicas
each. Efflux in 4F2hc-transfected cells to medium containing no amino
acids, or 1 mmol/L Ala, Ser, or Leu were 2.6 ± 0.1, 2.7 ± 0.3, 3.4 ± 0.1,
and 2.6 ± 0.3 nmol alanine/mg protein in 15 seconds, respectively. The
intracellular alanine content after 5 minutes’ incubation with 50 lmol/L
alanine was 65 ± 9, 71 ± 4, and 77 ± 6 in 4F2hc-, wild-type asc-1–, and
asc-1 (E112D)–transfected cells, respectively (N = 2).
neutral amino acids for these transporters. In contrast, the
other members of the HAT family behave as obligatory
exchangers [1].
The characteristics of asc-1 suggested SLC7A10 as a
candidate gene for cystinuria [29]. In fact, the exhaustive
mutational analysis of the coding region and the exon-
intron boundaries of the two cystinuria genes (SLC3A1
and SLC7A9) in the cohort of patients of the Inter-
national Cystinuria Consortium have failed to explain
∼13% of the alleles [31] (and manuscript in prepara-
tion). The unexplained alleles might correspond to mu-
tations in the promoter or intronic sequences of SLC3A1
or SLC7A9, or to mutations in unidentified genes. The
present study does not support a role for SLC7A10 in
cystinuria for several reasons. First, here we showed that
human asc-1 is not expressed in proximal tubule. The bulk
of the renal reabsorption of amino acids occurs in the
proximal tubule [37]. Moreover, transporters that play a
major role in renal reabsorption of amino acids mainly lo-
calized to the proximal tubule: (1) the apical transporter
b0,+AT/rBAT [3, 38–41], (2) the basolateral transporter
y+LAT-1/4F2hc [38], (3) the basolateral transporter LAT-
2/4F2hc [9, 38, 42], and (4) transporter EAAC1 [43], re-
sponsible for apical dicarboxylic amino acid reabsorption
as evidenced by the corresponding knockout mice [44].
Second, the exhaustive mutational analysis of the cod-
ing region and the exon-intron boundaries of SLC7A10
identified polymorphisms but not cystinuria-specific mu-
tations in 22 patients, which are not completely explained
by mutations in either of the two cystinuria genes. Third
and finally, none of the three previously reported vari-
ants in SLC7A10 associated with cystinuria predicts a dra-
matic change in the protein asc-1 [29]: a silent mutation
affecting residue serine 56, an intronic change which is not
likely to affect splicing, and a conservative missense mu-
tation (E112D) affecting a nonconserved residue in the
family of light subunits of HATs [16]. In the present study,
the expression of asc-1 (E112D) in HeLa cells demon-
strated full transport function. All this reveals that trans-
porter asc-1 plays neither a role in cystinuria and, most
probably, nor a role in renal reabsorption of cystine.
4F2hc acts as an ancillary protein to express asc-1 trans-
port activity in foreign expression systems. Thus, expres-
sion of asc-1 in oocytes does not result in induction of
amino acid transport, whereas coexpression with 4F2hc
does [16, 26] (and present study). In Hela cells, intracel-
lular endogenous 4F2hc serves for this purpose. Indeed,
transfection of asc-1 alone brings intracellular endoge-
nous 4F2hc to the cell membrane and results in the induc-
tion of asc transport activity (present study). However,
the functional coexpression of a light subunit and a heavy
subunit of HATs in a foreign expression system is not
a proof that these subunits heterodimerize in the na-
tive tissue. Thus, coexpression of rBAT or 4F2hc with
b0,+AT resulted in functional induction of amino acid
transport [19, 40, 45], whereas in kidney all b0,+AT het-
erodimerizes with rBAT and not with 4F2hc [3]. In-
deed, heterodimerization in native tissues or cells has also
been demonstrated for LAT-1/4F2hc [46, 47] and LAT-
2/4F2hc [48]. Renal expression of asc-1 localized to thin
limbs of Henle’s loop, distal tubules, and collecting ducts.
This localization does not coincide with the restrictive
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distribution of rBAT in proximal tubules [39, 41, 49].
In human kidney, 4F2hc has been localized to the ba-
solateral domain of epithelial cells of proximal tubules
[50]. Thus, expression of 4F2hc has not been reported
in distal nephron, but it could be underestimated due to
the high proximal expression of 4F2hc necessary to het-
erodimerize with y+LAT-1 and LAT-2, which are also
highly and specifically expressed in proximal nephron
[9, 38, 42]. If asc-1 forms heterodimers with 4F2hc, it
is expected that this transporter will have a basolateral
location in distal nephron. Alternatively, asc-1 might het-
erodimerize with an unknown heavy subunit. This pos-
sibility has been suggested for asc-2 and AGT-1. These
two subunits do not interact functionally with 4F2hc or
rBAT in foreign expression systems, and their functional
expression at the cell surface was accomplished by fu-
sion with these heavy subunits [5, 6]. Moreover, AGT-1
and asc-2 form a subgroup with low amino acid identity
with the other light subunits (24% to 33%). The amino
acid identity between the light subunits interacting with
4F2hc or rBAT ranges from 39% to 70%. Indeed, asc-
1 has 62% amino acid sequence identity with LAT-2.
Then, even though the interaction of asc-1 with uniden-
tified heavy subunits has not been ruled out, it seems
unlikely.
Recycling of L- and D-alanine and L-serine has been
described between Henle’s loops and vasa recta in the
juxtamedullary nephrons of the rat kidney [51–53]. The
flux of L- and D-alanine from vasa recta to the loops
can be partially inhibited by L-phenylalanine [53]. These
characteristics resemble those of the transport activity
induced by asc-1/4F2hc in oocytes [16, 26] and HeLa
cells (present study). The location of asc-1 in the thin
limbs of Henle’s loop strongly suggests that this trans-
porter may be responsible for the basolateral fluxes of
small neutral amino acids between tubule epithelial cells
and vasa recta during recycling. The recycling of amino
acids has been suggested to play a role in osmotic regu-
lation [51]. Moreover, free amino acids are believed to
participate in the osmotic adaptation of medullary cells,
even though with a lower quantitative contribution than
trimethylamines and polyols. In general, the content of
free amino acids in renal medulla changes according to
the diuretic state [54]. Taurine, alanine and proline are
the main free amino acids involved in the increase of
amino acid concentration in hypertonic medulla [55]. Two
concentrative amino acid transporters may participate
in this process: the Na+/Cl−/taurine transporter (TAUT)
[56] and system A [likely due to isoforms ATA2 and/or
NAT3 (also named ATA3)], which are expressed in kid-
ney [57, 58]. In this sense, hypertonic Madin-Darby ca-
nine kidney (MDCK) cells show increased expression of
TAUT mRNA [56] and system A transport activity [59,
60]. It has been suggested that free amino acids may play
a role in the initial stage of the cellular adaptation in
renal medulla, while the slowly accumulating trimethy-
lamines and polyols predominate when these cells are
fully adapted [61]. Indeed, the hypertonic activation of
betaine [60] and myo-inositol carriers [62] is slower that
the transitory stimulation of system A in MDCK cells.
On the other hand, hyposmolarity reduces the intracel-
lular content of amino acids in MDCK by stimulating
their release [63]. Beta-alanine, glycine, alanine, and ser-
ine, preferred substrates of transporter asc-1/4F2hc [16],
are among the most affected amino acids. Net efflux
through transporter asc-1/4F2hc, due to its facilitated dif-
fusion mode of transport, might be responsible for the
release of small neutral amino acids after their
hypertonic-induced transient accumulation or in hypos-
motic conditions.
Interestingly, asc-2, but not asc-1, is expressed in mouse
kidney, specifically in the collecting duct [6, 16]. Simi-
larly to asc-1, asc-2 also shows significant facilitated dif-
fusion mode of transport [6]. Moreover, asc-2 is not
found in the human genome. Thus, BLAST search in
the human genome sequence, using asc-2 as a query, re-
vealed all the identified light subunits of heteromeric
amino acid transporters but not the human ortholog
of asc-2. This suggests that mouse asc-2 might have a
role in osmotic adaptation in distal nephron similar to
that suggested for human asc-1. Interestingly to this re-
gard, analysis of asc-1 and asc-2 gene sequences revealed
the presence of tonicity-responsive enhancers (TonEs).
TonE motifs and TonE binding protein (TonEBP) medi-
ate the hypertonicity-induced increase in the transcrip-
tion of several genes like betaine transporter (BGT1),
myo-inositol transporter (SMIT), and aldose reductase
[55]. TonE consensus sequences TGGAAANNYNY [55]
(Y is C or T; N is any nucleotide) are located upstream and
within the first intron of human asc-1 and mouse asc-2.
One TonE element is present at ∼4 kb upstream of both
human asc-1 and mouse asc-2 exon 1, and one and six
TonE elements are located within the large first intron of
human asc-1 and mouse asc-2, respectively. In addition,
four and nine less restricted TonE consensus sequences
(YGGAANNNYNY) [64] are also present within the 10
kb upstream to the first exon 1 of human asc-1 and within
the first intron of mouse asc-2, respectively. Further
research is needed to assess the role of asc-1 and asc-2 in
kidney, but their expression in human and mouse distal
nephron, facilitated diffusion mode of transport and the
presence of TonE elements in their coding genes suggests
a role in osmotic adaptation.
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